Frailty and chronic lymphocytic leukemia: navigating challenges to improve outcomes
Personalized therapy planning that optimizes efficacy while mitigating toxicity in elderly/frail patients should be pursued. Future trials should ideally compare fixed-duration versus continuous therapy in well-characterized older or frail cohorts, with explicit objectives to enhance real-world applicability.
Authors
- Stefano Molica
Institutions
- Hull York Medical School (GB)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2026-03-17
- DOI
- https://doi.org/10.1080/17474086.2026.2647258
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00